Albendazole for lymphatic filariasis

Comparison 1 Albendazole versus placebo, Outcome 1 Microfilariae (mf ) prevalence: all participants (both mf positive or negative at baseline). . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 1.2.Comparison 1 Albendazole versus placebo, Outcome 2 Microfilariae (mf ) prevalence: only participants mf positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 1.3.Comparison 1 Albendazole versus placebo, Outcome 3 Antigen prevalence: all participants (both mf positive or negative at baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 1.4.Comparison 1 Albendazole versus placebo, Outcome 4 New clinical disease. . . . . . . . . . .Analysis 1.5.Comparison 1 Albendazole versus placebo, Outcome 5 Pre-existing clinical disease. . . . . . . .Analysis 1.6.Comparison 1 Albendazole versus placebo, Outcome 6 Adverse events. . . . . . . . . . . . .Analysis 2.1.Comparison 2 Albendazole versus ivermectin, Outcome 1 Microfilariae (mf ) prevalence: all participants (both mf positive or negative at baseline). . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 2.2.Comparison 2 Albendazole versus ivermectin, Outcome 2 Microfilariae (mf ) prevalence: only participants mf positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 2.3.Comparison 2 Albendazole versus ivermectin, Outcome 3 Antigen prevalence: all participants (antigen positive or negative at baseline). . . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 2.4.Comparison 2 Albendazole versus ivermectin, Outcome 4 New clinical disease. . . . . . . . . .Analysis 2.5.Comparison 2 Albendazole versus ivermectin, Outcome 5 Pre-existing clinical disease. . . . . . .Analysis 2.6.Comparison 2 Albendazole versus ivermectin, Outcome 6 Adverse events. . . . . . . . . . .Analysis 3.1.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 1 Microfilariae (mf ) prevalence: all participants (both mf positive or negative at baseline). . . . . . . . . . . . . . . . . . . . .Analysis 3.2.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 2 Microfilariae (mf ) prevalence: only participants mf positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 3.3.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 3 Antigen prevalence: all participants (antigen positive or negative) at baseline. . . . . . . . . . . . . . . . . . . . . . . . .Analysis 3.4.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 4 Antigen prevalence: only participants antigen positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 3.5.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 5 New clinical disease. . . .Analysis 3.6.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 6 Pre-existing clinical disease. .Analysis 3.7.Comparison 3 Albendazole plus ivermectin versus ivermectin, Outcome 7 Adverse events. . . . . .Analysis 4.1.Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 1 Microfiliariae (mf ) prevalence: all participants (both mf positive or negative at baseline). . . . . . . . . . . . . . . . . . . . .Analysis 4.2.Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 2 Microfilariae (mf ) prevalence: only participants mf positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 4.3.Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 3 Antigen prevalence: all participants (both antigen positive or negative at baseline). . . . . . . . . . . . . . . . . . . . . . . .Analysis 4.4.Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 4 Antigen prevalence: only participants antigen positive at baseline. . . . . . . . . . . . . . . . . . . . . . . . . .Analysis 4.5.Comparison 4 Albendazole versus diethylcarbamazine (DEC), Outcome 5 Adverse events. . . . . .i Albendazole for lymphatic filariasis (Review)